These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836 [TBL] [Abstract][Full Text] [Related]
47. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120 [TBL] [Abstract][Full Text] [Related]
48. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia. Juhl A Nephron; 1986; 43(4):305-6. PubMed ID: 3090461 [No Abstract] [Full Text] [Related]
49. DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome. Schmitz-Huebner U; Balleisen L; Arends P; Pollmann H; Sutor AH Haemostasis; 1980; 9(4):204-13. PubMed ID: 6772527 [TBL] [Abstract][Full Text] [Related]
50. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease. Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673 [TBL] [Abstract][Full Text] [Related]
51. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Sarembock IJ; Gertz SD; Gimple LW; Owen RM; Powers ER; Roberts WC Circulation; 1991 Jul; 84(1):232-43. PubMed ID: 1829399 [TBL] [Abstract][Full Text] [Related]
52. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Deschênes I; Finkle CD; Winocour PD Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808 [TBL] [Abstract][Full Text] [Related]
53. Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease. Mannucci PM; Cattaneo M Haemostasis; 1992; 22(5):276-80. PubMed ID: 1478539 [TBL] [Abstract][Full Text] [Related]
54. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Agnelli G; Pascucci C; Cosmi B; Nenci GG Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121 [TBL] [Abstract][Full Text] [Related]
55. Bleeding time prolongation with streptokinase and its reduction with 1-desamino-8-D-arginine vasopressin. Johnstone MT; Andrews T; Ware JA; Rudd MA; George D; Weinstein M; Loscalzo J Circulation; 1990 Dec; 82(6):2142-51. PubMed ID: 2242538 [TBL] [Abstract][Full Text] [Related]
56. IIB von Willebrand's disease: pathogenetic and therapeutic studies. Kyrle PA; Niessner H; Dent J; Panzer S; Brenner B; Zimmerman TS; Lechner K Br J Haematol; 1988 May; 69(1):55-9. PubMed ID: 3132965 [TBL] [Abstract][Full Text] [Related]
57. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Elg M; Carlsson S; Gustafsson D Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338 [TBL] [Abstract][Full Text] [Related]
58. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits. Kouz J; Czech J; Nicolay U; Dickneite G Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128 [TBL] [Abstract][Full Text] [Related]
59. Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release. Soslau G; Schwartz AB; Putatunda B; Conroy JD; Parker J; Abel RF; Brodsky I Am J Med Sci; 1990 Dec; 300(6):372-9. PubMed ID: 2264575 [TBL] [Abstract][Full Text] [Related]
60. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]